Abstract: The present application relates to therapeutics and pharmaceutical compositions, their use and also methods for preventing post-traumatic osteoarthritis, early or late stage, using compounds which inhibit either, or both, AMPA and KA glutamate receptors (Glu Rs).

Abstract: The method according to the present invention is a method for purifying a compound represented by a specific formula (1) or a resin having a structure represented by a specific formula (2), the method including a step of bringing a solution (A) including an organic solvent optionally immiscible with water, and the compound or the resin into contact with an acidic aqueous solution.

Abstract: The present invention provides a process for the production of furan, said process comprising the steps of: i) contacting furfural with a decarbonylation catalyst in a decarbonylation reactor to produce a gaseous decarbonylation reaction product stream comprising furan and carbon monoxide; ii) contacting said gaseous decarbonylation reaction product stream with a solvent stream comprising furfural; iii) absorbing at least a portion of the furan present in the gaseous decarbonylation reaction product stream into the solvent stream to provide a furan-containing solvent stream and a gaseous stream comprising carbon monoxide; iv) separating the furan from the furan containing solvent stream by distillation to provide a first furan stream; and v) using at least a portion of the remaining solvent stream comprising furfural as at least a portion of the furfural provided to the decarbonylation reactor.

Abstract: In an example, a method of butadiene sequestration includes receiving an input stream that includes butadiene. The method includes directing the input stream to a first sulfur dioxide charged zeolite bed for butadiene sequestration via a first chemical reaction of butadiene and sulfur dioxide to form sulfolene.

Abstract: The present invention relates to a process comprising converting a compound of formula (I) into a compound of formula (II) by reaction with an organolithium reagent, which compound can be further converted into duocarmycin analogs consisting of a DNA-alkylating and a DNA-binding part, and still further into corresponding antibody-drug conjugates.

Abstract: The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition.

Abstract: The present disclosure provides the design and synthesis of novel steroidal compounds that cause down-regulation of the androgen receptor (AR), both full length and splice variant. The compounds are potential agents for the treatment of all forms of prostate cancer and other diseases that depend on functional AR.

Abstract: A process is provided for improved levulinic acid production form biomass, wherein furfural is recovered from vapor flow from the levulinic acid production reactor. The reaction conditions can be chosen to enable good yield for both products and minimization of undesired side products.

Abstract: Disclosed is a composition including a fish oil and a juice in an oil-in-water emulsion for use in treatment and post-treatment of cancer.

Abstract: Disclosed herein are compositions and methods of making phenolic compounds and phenolic resins. The resins include multifunctional epoxies, amino glycidyl derivatives, alkanoate derivatives, alkyl ether derivatives, and multi-functional amines prepared from hydroxymethyl derivatives of novolac resin.

Abstract: A method for the production of ethylene oxide wherein the partial pressure of water vapor at the inlet of the reactor is at least about 8 kPa using a high purity carrier comprising alpha-alumina, a promoting amount of at least one Group IA metal, and a promoting amount of rhenium.

Abstract: The present invention provides crystalline solid and amorphous forms of (?)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (?)-halofenate.

Abstract: Aspects described herein relate to food and beverage compositions infused with lipophilic active agents and methods of use for the treatment of a variety of disorders. More particularly, aspects described herein relate to food and beverage compositions infused with lipophilic active agents such as cannabinoids, nicotine, nonsteroidal anti-inflammatories (NSAIDs), and vitamins, that provide enhanced bioavailability of the lipophilic active agents in a subject, and that mask unpleasant tastes of lipophilic active agents.

Abstract: A process for reducing the bacterial count on a poultry carcass during poultry processing after the picking stage and prior to the chilling stage by applying an intervention solution having at least one equilibrium peroxycarboxylic acid or a pH modified peroxycarboxylic acid comprising peroxyacetic acid to the poultry carcass at an elevated temperature above 100° F. and at an elevated concentration of at least 200 ppm for a desired period of time of less than about 30 seconds to reduce the bacterial count by at least 60 percent. The process providing acceptable antimicrobial control in poultry processing prior to the chilling stage.

Abstract: A process for preparation of (2S, 5R)-7-oxo-6-sulphooxy-2-[((3R)-piperidine-3-carbonyl)-hydrazino carbonyl]-1,6-diaza-bicyclo[3.2.1]octane is disclosed.

Abstract: The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).

Abstract: The present invention relates to waxes useful for cosmetic applications having stable oil-in-water emulsion-forming properties and, in some embodiments, stable gel-in-water-forming properties. In some embodiments, the waxes exhibit self-emulsifying properties, and can be produced without the addition of any other substances to achieve the emulsion (e.g., co-emulsifiers, hydrophilic polymers, polar surfactants, rheological modifiers, gelling agents). The waxes generally comprise: (a) polyglyceryl fatty acid ester, (b) a glycerol fatty acid ester, and 9c) a fatty alcohol. In particular embodiments, the polyglyceryl fatty acid ester can be a polyglyceryl-2, -3, or -4 fatty acid ester, and the fatty chain lengths of (a)-(c) can range from C12 to C22. In more particular embodiments, the waxes can comprise polyglyceryl stearate, glyceryl stearate, and stearyl alcohol. Gels, oil-in-water emulsions, and other compositions produced from the waxes, as well as uses and methods relating thereto, are also disclosed.

Abstract: The present invention provides an inhalation-type pharmaceutical composition for hypertension and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising propranolol, captopril, amlodipine besylate, losartan, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.

Abstract: (S)-pirlindole or its pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising the same for use in the therapeutic treatment and prevention of pain.